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Abstract: We assessed the predictive ability of selected biomarkers using N-terminal  
pro-brain natriuretic peptide (NT-proBNP) as the benchmark and tried to establish a 
multi-biomarker approach to heart failure (HF) in hypertensive patients. In 120 hypertensive 
patients with or without overt heart failure, the incremental predictive value of the following 
biomarkers was investigated: Collagen III N-terminal propeptide (PIIINP), cystatin C 
(CysC), lipocalin-2/NGAL, syndecan-4, tumor necrosis factor-α (TNF-α), interleukin 1 
receptor type I (IL1R1), galectin-3, cardiotrophin-1 (CT-1), transforming growth factor β 
(TGF-β) and N-terminal pro-brain natriuretic peptide (NT-proBNP). The highest discriminative 
value for HF was observed for NT-proBNP (area under the receiver operating characteristic 
curve (AUC) = 0.873) and TGF-β (AUC = 0.878). On the basis of ROC curve analysis 
we found that CT-1 > 152 pg/mL, TGF-β < 7.7 ng/mL, syndecan > 2.3 ng/mL, NT-proBNP > 
332.5 pg/mL, CysC > 1 mg/L and NGAL > 39.9 ng/mL were significant predictors of overt 
HF. There was only a small improvement in predictive ability of the multi-biomarker panel 
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including the four biomarkers with the best performance in the detection of HF—NT-proBNP, 
TGF-β, CT-1, CysC—compared to the panel with NT-proBNP, TGF-β and CT-1 only. 
Biomarkers with different pathophysiological backgrounds (NT-proBNP, TGF-β, CT-1, 
CysC) give additive prognostic value for incident HF in hypertensive patients compared to  
NT-proBNP alone. 
Keywords: hypertension; biomarkers; heart failure 
 
1. Introduction 
Hypertension is a major contributor to the development of heart failure (HF). Our understanding of  
the epidemiology and pathophysiology of HF in relation to hypertension has increased considerably  
in recent years. Currently, we are aware of the fact that the pathophysiologic relationship between 
hypertension and heart failure is more complex than simply the development of left ventricular 
hypertrophy. A growing array of biological pathways support the syndrome we recognize as heart 
failure. These include deleterious pathways promoting heart failure development and progression,  
as well as compensatory cardioprotective pathways. Components of these pathways can be utilized  
as biomarkers of this condition in order to facilitate the diagnosis and prognostication and potentially 
direct the management [1]. 
Brain natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) are widely 
studied factors, having a potentially important but still evolving role in prognosis determination and 
as a surrogate endpoint in clinical trials [2]. BNP and NT-proBNP exert a natriuretic as well as an  
anti-fibrotic effect [3]. They are secreted mainly from the ventricle in response to myocardial stretch, 
i.e., the elevation of the left ventricular (LV) filling pressure [4]. Measuring the plasma BNP level is 
useful to differentiate between heart failure and other causes of dyspnea upon presentation to the 
emergency room [5]. Such measures have been shown to provide prognostic information on mortality 
and the occurrence of major cardiovascular events, not only in patients with chronic heart failure but 
also in the general population, and they can improve patient management [6,7]. As a complex disease, 
heart failure is associated with various pathophysiological and biochemical disorders. No single 
biomarker is able to detect all these features [8]. 
After the analysis of available literature concerning biomarkers in the databases including PubMed 
and MEDLINE and based on our preliminary results [9,10], we chose the most promising biomarkers 
relevant to their underlying pathophysiology: transforming growth factor β (TGF-β), cystatin C (CysC), 
neutrophil gelatinase-associated lipocalin 2 (NGAL), galectin-3, collagen III N-terminal propeptide 
(PIIINP), syndecan, tumor necrosis factor α (TNF-α), cardiotrophin 1 (CT-1), interleukin 1 receptor, 
type I (IL1R1) and NT-proBNP. We stated the hypothesis that biomarkers which reflects different 
biological pathways may give additional predictive information in patients with hypertension. Therefore 
the purpose of the current study was to evaluate which heart failure biomarkers may be of value when 
combined in a multi-marker panel with the biochemical gold standard NT-proBNP. 
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2. Results and Discussion 
2.1. General Characteristics of Patients 
Patients’ characteristics are presented in Table 1. In the HF group compared to the non-HF group: 
There were more males and patients with diabetes mellitus, patients more frequently reported 
stenocardia, and they had significantly lower blood pressure and MDRD GFR. In the HF group, statins, 
loop diuretics, spironolactone/eplerenone, ACE inhibitors and digoxin were used more frequently. 
Calcium channel blockers and sartans were used more frequently in patients with hypertension but 
without overt heart failure. 
Compared to non-HF patients, HF hypertensive patients had significantly lower values of TGF-β, 
and higher levels of NGAL, CT-1, syndecan, NT-proBNP and CysC (p < 0.0001; p = 0.007; p < 0.0001; 
p < 0.0001; p < 0.0001 and p < 0.0001 respectively). The detailed data on biomarkers in study groups is 
presented in Table 1. 
Table 1. Characteristics of patients and standard echocardiographic parameters in each group. 
Parameter 
Mean ± Standard Deviation (SD) p 
Non-HF Group n = 60 HF Group n = 60 Non-HF vs. HF 
Age (years) 61.76 ± 11 64.54 ± 11 0.57 
BMI (kg/m2) 27.38 ± 4 28.66 ± 4 0.16 
GFR MDRD (mL/min/1.73 m2) 89.31 ± 6 67.72 ± 24 0.0001 
Systolic BP (mmHg) 135.82 ± 8 122.28 ± 14 0.0001 
Diastolic BP (mmHg) 82.00 ± 8 75.72 ± 8 0.0001 
HR (bpm) 70.57 ± 4 74.34 ± 9 0.09 
Hemoglobin (g/dL) 14.38 ± 0.96 13.87 ± 1 0.11 
Galectin-3 (ng/mL) 21.27 ± 5 18.59 ± 11 0.43 
TNF-α (pg/mL) 32.63 ± 44 30.94 ± 16 0.23 
CT-1 (pg/mL) 89.13 ± 115 229.51 ± 129.7 <0.0001 
TGF-β (ng/mL) 10.67 ± 2.92 5.98 ± 2 <0.0001 
Syndecan (ng/mL) 1.39 ± 1.08 4.14 ± 3 <0.0001 
NT-proBNP (pg/mL) 150.12 ± 115 1889.03 ± 336 <0.0001 
CysC (mg/L) 0.81 ± 0.44 1.37 ± 0.83 <0.0001 
NGAL (ng/mL) 50.71 ± 45  64.96 ± 36 0.007 
PIIINP (ng/mL) 2.21 ± 1 2.62 ± 0.97 0.06 
IL1R1(ng/mL) 0.45 ± 0.31 0.35 ± 0.19 0.05 
CRP (mg/L) 2.26 ± 1 3.60 ± 4.70 0.95 
LVEDD (mm) 49.86 ± 5 63.22 ± 9 <0.0001 
LVESD (mm) 31.65 ± 5 48.10 ± 10 <0.0001 
LVEF (%) 60.92 ± 4 36.70 ± 10 <0.0001 
LA (mm) 36.59 ± 5 45.14 ± 7 <0.0001 
peak E (cm/s) 70.84 ± 15 62.90 ± 23 0.19 
peak A (cm/s) 68.10 ± 19 87.40 ± 13 0.01 
E/A ratio 1.10 ± 0.38 0.66 ± 0.25 0.008 
DT (ms) 257.88 ± 66 343.17 ± 106 0.04 
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Table 1. Cont. 
Parameter 
Mean ± Standard Deviation (SD) p 
Non-HF Group n = 60 HF Group n = 60 Non-HF vs. HF 
IVSD (mm) 9.39 ± 2 11.77 ± 2 <0.0001 
PWD (mm) 9.29 ± 1 11.33 ± 2 0.002 
RVdD (mm) 27.31 ± 3 28.82 ± 4 0.08 
LVEDV (mL) 83.44 ± 23 213.59 ± 60 <0.0001 
LVESV (mL) 29.06 ± 8 135.55 ± 50 <0.0001 
TAPSE (mm) 25.16 ± 3 21.67 ± 3 0.005 
Parameter 
Number of Patients (%) 
p 
Non-HF Group; n = 60 HF Group; n = 60 
Gender (male) 22 (45) 43 (86) <0.0001 
Smoking 4 (8) 2 (4) 0.65 
Heart failure acc. to NYHA 
I 35 (72) 5 (10) 
0.0001 
II 14 (28) 21 (42) 
III 0 24 (48) 
IV 0 0 
Stenocardia acc. to CCS 
0 27 (55) 2 (4) 
0.0001 
I 5 (10) 34 (68) 
II 17 (34) 13 (26) 
III 0 1 (2) 
Diabetes mellitus or  
abnormal glucose level 
9 (18) 19 (38) 0.03 
Statins 21 (43) 32 (64) 0.03 
Insulin 4 (8) 3 (6) 0.97 
Loop diuretics 21 (42) 46 (92) <0.0001 
Β-blockers 17 (77) 26 (96) 0.06 
Spironolactone/eplerenone 7 (14) 41 (82) 0.01 
Acetylsalicylic acid 17 (35) 26 (53) 0.06 
ACE inhibitors 22 (45) 43 (86) <0.0001 
Sartans (ARBs) 22 (45) 8 (16) 0.001 
Calcium channel blockers 16 (32) 4 (8) 0.005 
Digoxin 0 12 (24) 0.0008 
BMI, body mass index; GFR MDRD, glomerular filtration rate on the basis of the study “Modification of Diet 
in Renal Disease”; BP, blood pressure; HR, heart rate; bpm, beats per minute; TGF-β, transforming growth 
factor β; NT-proBNP, N-terminal pro-brain natriuretic peptide; CysC, cystatin C; NGAL, neutrophil 
gelatinase-associated lipocalin 2; PIIINP, collagen III N-terminal propeptide; TNF-α, tumor necrosis factor α; 
CT-1, cardiotrophin 1; IL1R1, interleukin 1 receptor, type I; LVEDD, left ventricular end-diastolic 
diameter; LVESD, left ventricular end-systolic diameter; LVEF, left ventricular ejection fraction; LA, left 
atrial diameter; E, early mitral diastolic inflow velocity; A, late mitral diastolic inflow velocity; E/A, ratio of 
early to late mitral inflow velocities; DT, deceleration time of peak early mitral filling velocity; IVSD, diastolic 
interventricular septal thickness; PWD, diastolic posterior wall thickness; RVDD, right ventricular diastolic 
diameter; LVEDV, left ventricular end-diastolic volume; LVSV, left ventricular systolic volume; TAPSE, 
tricuspid annular plane systolic excursion; ACE, angiotensin-converting enzyme. 
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Compared to the non-HF group, patients with overt heart failure had: larger left ventricular (LV) 
dimensions (p < 0.0001) and LV volumes (p < 0.0001), lower left ventricular ejection fraction (LVEF) 
(p < 0.0001), significantly increased left atrial (LA) diameter (p < 0.0001), greater wall thickness of the 
left ventricle (<0.0001, 0.002), lower late mitral diastolic inflow velocity (A) (p = 0.01), lower ratio of 
early to late mitral inflow velocities (E/A ratio) (p < 0.008), longer deceleration time of peak early mitral 
filling velocity (DT) (p = 0.04) and lower tricuspid annular plane systolic excursion (TAPSE)  
(p = 0.005) (Table 1). 
2.2. Assessment of Biomarkers 
All biomarkers analyzed in this study were used in the assessment of heart failure discriminative 
value. Biomarkers with significant AUC (CT-1, TGF-β, syndecan, NT-proBNP, CysC, NGAL), which 
may facilitate the diagnosis of heart failure, are presented in Table 2. The highest discriminative value 
for heart failure was observed for NT-proBNP (AUC 0.873; p = 0.0001; 95% CI (0.803–0.943))  
and TGF-β (AUC 0.878; p = 0.0001; 95% CI (0.811–0.944))—Figures 1 and 2. Patients with overt heart 
failure had higher levels of NT-proBNP and lower levels of TGF-β. 
Table 2. Biomarkers with significant discriminative value for heart failure. 
Biomarker AUC Standard Error—SE p 95% CI 
CT-1 0.831 0.045 0.0001 0.743 0.918 
TGF-β 0.878 0.034 0.0001 0.811 0.944 
Syndecan 0.781 0.047 0.0001 0.689 0.873 
NT-proBNP 0.873 0.036 0.0001 0.803 0.943 
CysC 0.793 0.045 0.0001 0.705 0.881 
NGAL 0.673 0.065 0.007 0.545 0.802 
AUC, area under the curve; CT-1, cardiotrophin 1; TGF-β, transforming growth factor β; NT-proBNP,  
N-terminal pro-brain natriuretic peptide; CysC, cystatin C; NGAL, neutrophil gelatinase-associated lipocalin 2. 
 
Figure 1. Receiver-operating characteristic curve (ROC) for the TGF-β variable (AUC 0.878; 
p = 0.0001; 95% CI (0.811–0.944)) revealing its diagnostic potential for HF. 
Int. J. Mol. Sci. 2015, 16 10720 
 
 
 
Figure 2. ROC for the NT-proBNP variable (AUC 0.873; p = 0.0001; 95% CI (0.803–0.943)) 
revealing its diagnostic potential for HF. 
On the basis of receiver-operating characteristic (ROC) curve analysis we found that  
CT-1 > 152 pg/mL, TGF-β < 7.7 ng/mL, syndecan > 2.3 ng/mL, NT-proBNP > 332.5 pg/mL, CysC > 1 mg/L 
and NGAL > 39.9 ng/mL were significant predictors of overt heart failure in patients with hypertension. 
The optimal cut-off points of biomarkers for the occurrence of overt heart failure in patients with 
hypertension are presented in Table 3. 
Table 3. Optimal cut-off points of biomarker levels for the occurrence of overt heart failure 
in patients with hypertension designated on the basis of ROC curves. 
Meters 
CT-1  
≥152.2 pg/mL 
TGF-β  
≤7.7 ng/mL 
Syndecan 
≥2.3 ng/mL 
NT-proBNP  
≥332.5 pg/mL 
CysC  
≥1.0 mg/L 
NGAL  
˃39.9 ng/mL 
Sensitivity 0.77 0.72 0.64 0.76 0.62 0.58 
Specificity 0.85 0.91 0.87 0.95 0.83 0.81 
PPV 0.83 0.90 0.83 0.95 0.78 0.68 
NPV 0.80 0.76 0.71 0.79 0.69 0.74 
OR 20.50 28.92 13.06 74.41 8.54 6.34 
OR (−95% CI) 7.05 8.76 4.62 15.68 3.28 2.34 
OR (+95% CI) 59.52 95.52 36.93 353.01 22.23 17.16 
p 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 
CT-1, cardiotrophin 1; TGF-β, transforming growth factor β; NT-proBNP, N-terminal pro-brain natriuretic 
peptide; CysC, cystatin C; NGAL, neutrophil gelatinase-associated lipocalin 2; PPV, positive predictive value; 
NPV, negative predictive value; OR, odds ratio. 
2.3. Predictive Value of Selected Biomarkers in Univariate and Multivariate Regression Analysis 
To evaluate the predictive value of selected biomarkers, multivariate models were used. 
In univariate analysis, biomarkers which statistically significantly increased the risk of overt heart 
failure were as follows: CT-1, TGF-β, syndecan, NT-proBNP and CysC (p < 0.0001). The highest 
discriminative value was found for NT-proBNP and TGF-β (c statistic—0.873; 0.878, respectively). 
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Higher values of NT-proBNP, CT-1, syndecan and CysC and a lower level of TGF-β increased  
the risk of heart failure. The results are summarized in Table 4. 
Table 4. Biomarkers with statistically significant diagnostic value for heart failure in 
univariate analysis. 
Analysis Variable Parameter—B SE p OR 95% CI c Statistic 
Univariate 
analysis 
Galectin-3 −0.039 0.027 0.145 0.961 0.912 1.014 0.549 
TNF-α −0.002 0.006 0.800 0.998 0.986 1.011 0.418 
CT-1 0.010 0.002 0.000 1.010 1.006 1.015 0.830 
TGF-β −0.630 0.124 0.000 0.533 0.418 0.679 0.878 
Syndecan 0.675 0.173 0.000 1.964 1.398 2.759 0.781 
NT-proBNP 0.007 0.002 0.000 1.007 1.003 1.010 0.873 
CysC 2.714 0.742 0.000 15.091 3.523 64.645 0.793 
NGAL −0.010 0.006 0.123 0.990 0.978 1.003 0.673 
PIIINP 0.374 0.206 0.069 1.454 0.971 2.177 0.590 
IL1R1 −1.640 0.850 0.054 0.194 0.037 1.025 0.587 
CRP 0.153 0.093 0.099 1.165 0.972 1.398 0.504 
TNF-α, tumor necrosis factor α; CT-1, cardiotrophin 1; TGF-β, transforming growth factor β; NT-proBNP,  
N-terminal pro-brain natriuretic peptide; CysC, cystatin C; NGAL, neutrophil gelatinase-associated lipocalin 2; 
PIIINP, collagen III N-terminal propeptide; IL1R1, interleukin 1 receptor, type I; CRP, C-reactive protein. 
We assessed the usefulness of biomarkers in the diagnosis of heart failure using NT-proBNP as  
a benchmark. TGF-β was the only biomarker indicative of heart failure in the same way as NT-proBNP. 
Other biomarkers were worse indicators of heart failure in patients with hypertension compared to  
NT-proBNP. Data are presented in Table 5. 
Table 5. Usefulness of biomarkers in the diagnosis of heart failure in comparison to the basic 
model (NT-proBNP). 
Comparison of  
Models—NT-proBNP vs.: 
Measure 
Galectin-3 
NRI (Categorical) (95% CI): −0.3963 (−0.6305–−0.162); p-value: 0.00092 
NRI (Continuous) (95% CI): −1.1735 (−1.524–−0.8229); p-value: 0.00000 
IDI (95% CI): −0.4621 (−0.5864–−0.3379); p-value: 0.00000 
TNF-α 
NRI (Categorical) (95% CI): −0.6513 (−0.8–−0.5026); p-value: 0.00000 
NRI (Continuous) (95% CI): −1.4765 (−1.7278–−1.2252); p-value: 0.00000 
IDI (95% CI): −0.4962 (−0.5948–−0.3975); p-value: 0.00000 
CT-1 
NRI (Categorical) (95% CI): −0.0625 (−0.2909–0.1659); p-value: 0.59176 
NRI (Continuous) (95% CI): −0.7111 (−1.091–−0.3312); p-value: 0.00024 
IDI (95% CI): −0.2023 (−0.3402–−0.0645); p-value: 0.00401 
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Table 5. Cont. 
Comparison of  
Models—NT-proBNP vs.: 
Measure 
TGF-β 
NRI (Categorical) (95% CI): −0.0816 (−0.2969–0.1336); p-value: 0.45731 
NRI (Continuous) (95% CI): −0.2188 (−0.6047–0.1671); p-value: 0.26649 
IDI (95% CI): −0.031 (−0.17–0.1079); p-value: 0.66165 
Syndecan 
NRI (Categorical) (95% CI): −0.1658 (−0.3694–0.0377); p-value: 0.11034 
NRI (Continuous) (95% CI): −0.7211 (−1.0922–−0.3499); p-value: 0.00014 
IDI (95% CI): −0.2204 (−0.345–−0.0958); p-value: 0.00053 
CysC 
NRI (Categorical) (95% CI): −0.2479 (−0.4714–−0.0244); p-value: 0.02974 
NRI (Continuous) (95% CI): −0.6811 (−1.0551–−0.3072); p-value: 0.00036 
IDI (95% CI): −0.2526 (−0.374–−0.1312); p-value: 0.00000 
NGAL 
NRI (Categorical) (95% CI): −0.4502 (−0.6725–−0.2279); p-value: 0.00000 
NRI (Continuous) (95% CI): −1.1261 (−1.4897–−0.7624); p-value: 0.00000 
IDI (95% CI): −0.4029 (−0.5347–−0.2711); p-value: 0.00000 
PIIINP 
NRI (Categorical) (95% CI): −0.5858 (−0.8364–−0.3352); p-value: 0.00000 
NRI (Continuous) (95% CI): −1.0872 (−1.4282–−0.7462); p-value: 0.00000 
IDI (95% CI): −0.4543 (−0.5718–−0.3368); p-value: 0.00000 
IL1R1 
NRI (Categorical) (95% CI): −0.595 (−0.853–−0.337); p-value: 0.00000 
NRI (Continuous) (95% CI): −1.2626 (−1.5716–−0.9535); p-value: 0.00000 
IDI (95% CI): −0.4404 (−0.5486–−0.3322); p-value: 0.00000 
CRP 
NRI (Categorical) (95% CI): −0.4872 (−0.7025–−0.2718); p-value: 0.00000 
NRI (Continuous) (95% CI): −0.9704 (−1.3663–−0.5745); p-value: 0.00000 
IDI (95% CI): −0.4035 (−0.5319–−0.2752); p-value: 0.00000 
TGF-β, transforming growth factor β; NT-proBNP, N-terminal pro-brain natriuretic peptide; CysC, cystatin C; 
NGAL, neutrophil gelatinase-associated lipocalin 2; PIIINP, collagen III N-terminal propeptide; TNF-α, tumor 
necrosis factor α; CT-1, cardiotrophin 1; IL1R1, interleukin 1 receptor type I; CRP, C-reactive protein. 
Comparison of the Basic Model of NT-proBNP with Models Extended by an Additional Biomarker 
The addition of TNF-α and IL1R1 to NT-proBNP did not improve the predictive value in comparison 
to NT-proBNP alone. There was a significant increase in the detection of heart failure in the combined 
measurement of concentrations of NT-proBNP and: galectin-3, CT-1, TGF-β, syndecan, CysC, NGAL, 
PIIINP, IL1R1 and CRP. The greatest significance was obtained in the case of the panel of NT-proBNP 
and TGF-β. Data are presented in Table 6. When the multi-marker (four biomarkers with the best 
performance: NT-proBNP, TGF-β, CT-1, CysC) approach was used, superior ability of heart failure 
recognition was observed in comparison to NT-proBNP alone. There was only a small improvement in 
the predictive value of the panel with NT-proBNP, TGF-β, CT-1 and CysC compared to the panel with 
NT-proBNP, TGF-β and CT-1 (Table 7). 
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Table 6. Comparison of the basic model of NT-proBNP with models extended by an 
additional biomarker. 
Comparison of  
Models—NT-proBNP vs.  
NT-proBNP + Additional 
Biomarker: 
Measure 
Galectin-3 
NRI (Categorical) (95% CI): −0.0147 (−0.1356–0.1061); p-value: 0.81102 
NRI (Continuous) (95% CI): 0.3401 (−0.0229–0.7031); p-value: 0.06627 
IDI (95% CI): 0.0534 (0.0143–0.0924); p-value: 0.00742 
TNF-α 
NRI (Categorical) (95% CI): −0.0417 (−0.099–0.0155); p-value: 0.15329 
NRI (Continuous) (95% CI): 0.0643 (−0.1991–0.3278); p-value: 0.63213 
IDI (95% CI): 0.0022 (−0.0113–0.0156); p-value: 0.75434 
Cardiotrophin 
NRI (Categorical) (95% CI): 0.0444 (−0.0876–0.1764); p-value: 0.5093 
NRI (Continuous) (95% CI): 1.175 (0.8603–1.4897); p-value: 0.00000 
IDI (95% CI): 0.1207 (0.0575–0.1839); p-value: 0.00018 
TGF-β 
NRI (Categorical) (95% CI): 0.1204 (−0.0246–0.2654); p-value: 0.10364 
NRI (Continuous) (95% CI): 1.2343 (0.9371–1.5315); p-value: 0.00000 
IDI (95% CI): 0.2139 (0.1314–0.2965); p-value: 0.00000 
Syndecan 
NRI (Categorical) (95% CI): 0.1029 (−0.0302–0.236); p-value: 0.12963 
NRI (Continuous) (95% CI): 1.0676 (0.7499–1.3853); p-value: 0.00000 
IDI (95% CI): 0.0979 (0.0417–0.1542); p-value: 0.00064 
Cystatin 
NRI (Categorical) (95% CI): −0.02 (−0.1089–0.0689); p-value: 0.6595 
NRI (Continuous) (95% CI): 1.0519 (0.7234–1.3803); p-value: 0.00000 
IDI (95% CI): 0.0733 (0.0257–0.1209); p-value: 0.00253 
NGAL 
NRI (Categorical) (95% CI): −0.009 (−0.0984–0.0804); p-value: 0.84352 
NRI (Continuous) (95% CI): 0.9628 (0.5862–1.3393); p-value: 0.00000 
IDI (95% CI): 0.0407 (−0.0015–0.0828); p-value: 0.05869 
PIIINP 
NRI (Categorical) (95% CI): 0.0204 (−0.0888–0.1297); p-value: 0.71427 
NRI (Continuous) (95% CI): 0.8242 (0.4631–1.1854); p-value: 0.00000 
IDI (95% CI): 0.0808 (0.0333–0.1283); p-value: 0.00086 
IL1R1 
NRI (Categorical) (95% CI): 0.0186 (−0.0516–0.0888); p-value: 0.60352 
NRI (Continuous) (95% CI): −0.0458 (−0.4257–0.3341); p-value: 0.81317 
IDI (95% CI): 0.0097 (−0.0029–0.0222); p-value: 0.13103 
CRP 
NRI (Categorical) (95% CI): 0.0086 (−0.0747–0.0919); p-value: 0.8404 
NRI (Continuous) (95% CI): 0.2581 (0.0396–0.4765); p-value: 0.02058 
IDI (95% CI): 0.0259 (0.0094–0.0423); p-value: 0.00206 
TGF-β, transforming growth factor β; NT-proBNP, N-terminal pro-brain natriuretic peptide; CysC, cystatin C; 
NGAL, neutrophil gelatinase-associated lipocalin 2; PIIINP, collagen III N-terminal propeptide; TNF-α, tumor 
necrosis factor α; CT-1, cardiotrophin 1; IL1R1, interleukin 1 receptor type I; CRP, C-reactive protein. 
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Table 7. Independent risk factors for heart failure in progressing logistic regression. 
Variable Parameter—B SE p OR 95% CI c Statistic 
NT-proBNP 0.008 0.003 0.003 1.008 1.003 1.014 
0.973 TGF-β −0.611 0.186 0.001 0.543 0.377 0.781 
CT-1 0.009 0.003 0.013 1.009 1.002 1.016 
NT-proBNP 0.010 0.004 0.008 1.010 1.003 1.017 
0.985 TGF-β −0.752 0.240 0.002 0.472 0.295 0.754 
CT-1 0.007 0.003 0.040 1.007 1.000 1.014 
CysC 2.490 1.046 0.017 12.058 1.551 93.720 
Comparison of the 3-Variable 
Model with the Model Only with  
NT-proBNP 
Comparison of the 4-Variable Model 
with the Model Only with  
NT-proBNP 
Comparison of the 4-Variable 
moDel with the 3-Variable Model
NRI (Categorical) (95% CI):  
0.1319 (−0.0225–0.2864);  
p-value: 0.0941 
NRI (Categorical) (95% CI):  
0.1333 (−0.031–0.2976);  
p-value: 0.11173 
NRI (Categorical) (95% CI):  
0.0014 (−0.0577–0.0604);  
p-value: 0.96323 
NRI (Continuous) (95% CI):  
1.6083 (1.3833–1.8333);  
p-value: 0.00000 
NRI (Continuous) (95% CI):  
1.6111 (1.3862–1.836);  
p-value: 0.00000 
NRI (Continuous) (95% CI):  
1.3278 (1.0407–1.6148);  
p-value: 0.00000 
IDI (95% CI):  
0.2637 (0.1761–0.3512);  
p-value: 0.00000 
IDI (95% CI):  
0.2982 (0.206–0.3904);  
p-value: 0.00000 
IDI (95% CI):  
0.0345 (−0.0011–0.0701);  
p-value: 0.0572 
NT-proBNP, N-terminal pro-brain natriuretic peptide; TGF-β, transforming growth factor β; CT-1, cardiotrophin; 
and CysC, cystatin C. 
2.4. Discussion 
2.4.1. Background 
Arterial hypertension is associated with chronic vascular inflammation and remodeling, contributing 
to progressive vascular damage and atherosclerosis. Changes in the heart in hypertension have been 
investigated for many years, and now we already know a lot about the remodeling that occurs in the 
heart, the coronary arteries and small capillaries delivering blood to the heart. An important issue is the 
identification of patients with hypertension at risk of developing this syndrome, the evaluation of new 
biochemical markers and new methods of diagnosis in this group of patients [11]. 
2.4.2. BNP/NT-proBNP as the Gold Standard Biomarker in Heart Failure 
The B-type natriuretic peptides BNP and NT-proBNP provide a cheap and accessible diagnostic test 
for heart failure (HF) and left ventricular dysfunction. Clinical guidelines advocate their use in the diagnostic 
work-up in case of HF suspicion to limit the number of potential cases requiring echocardiography by 
ruling out the condition where the natriuretic peptide level is low, although recommended rule-out  
cut-off points vary between studies and guidelines [12,13]. According to present ESC guidelines, the 
optimal exclusion cut-off point for NT-proBNP in patients presenting with acute onset or worsening of 
symptoms is 300 pg/mL. For patients presenting in a non-acute way, the optimum exclusion cut-off point 
is 125 pg/mL for NT-proBNP. The sensitivity and specificity of NT-proBNP for the diagnosis of HF are 
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lower in non-acute patients [13]. There are no significant differences in plasma concentration of  
NT-proBNP between patients with heart failure of various origins. 
However, in order to diagnose heart failure, knowledge of the non-cardiac factors that influence  
NT-proBNP is crucial. Anemia, which is common in heart and renal failure, is one of the independent 
factors affecting natriuretic peptides. In chronic kidney disease, anemia is mainly caused by the reduced 
erythropoietin production [14,15]. 
For these reasons, NT-proBNP was concluded to be of diagnostic value in patients with heart 
failure and proper renal functions. Previous studies have identified a variety of non-cardiac factors 
influencing natriuretic peptide levels, including age, sex, BMI, renal function, hepatic damage and 
diastolic pressure [16–18]. 
Not unexpectedly, BNP/NT-proBNP fails to fulfill all the criteria for an ideal biomarker. The selection 
of additional biomarkers and the development of the multi-biomarker approach will be an important step 
towards improving the diagnosis and the treatment of patients with chronic and acute decompensated 
heart failure. This study is the first investigating serum levels of PIIINP, CysC, lipocalin-2/NGAL, 
syndecan-4, tumor necrosis factor-α (TNF-α), interleukin 1 receptor type I (IL1R1), galectin-3, CT-1 
and TGF-β in patients with hypertension and heart failure. Furthermore, these biomarkers were compared 
with NT-proBNP—the gold standard biomarker in chronic heart failure. 
2.4.3. Short Description of the Results 
In this study we investigated in patients with hypertension the diagnostic and prognostic multi-marker 
approach towards heart failure using selected biomarkers (including galectin-3, CT-1, CysC, TNF-α, 
PIIINP, syndecan-4, IL1RL1, TGF-β and lipocalin-2) and using NT-proBNP as the benchmark. 
Compared to non-HF patients, HF hypertensive patients had significantly lower values of TGF-β, and 
higher levels of CT-1, NAGAL, syndecan, NT-proBNP and CysC (p < 0.0001; p = 0.007; p < 0.0001;  
p < 0.0001; p = 0.0001;and p < 0.0001, respectively). 
On the basis of receiver operating characteristic (ROC) curve analysis, we found that CT-1 > 152 pg/mL, 
TGF-β < 7.7 ng/mL, syndecan > 2.3 ng/mL, NT-proBNP > 332.5 pg/mL, CysC > 1 mg/L and  
NGAL > 39.9 ng/mL were significant predictors of overt heart failure in patients with hypertension.  
The highest discriminative values in univariate analysis were found for NT-proBNP and TGF-β  
(c statistic—0.873; 0.878 respectively). In the multi-biomarker approach, four biomarkers with the best 
performance in the detection of heart failure (NT-proBNP, TGF-β, CT-1, CysC) had superior value in 
the recognition of heart failure compared to NT-proBNP alone. There was only a small improvement in 
the predictive value of the multi-biomarker score with NT-proBNP, TGF-β, CT-1 and CysC compared 
to the panel comprising NT-proBNP, TGF-β and CT-1. 
2.4.4. The Multi-Biomarker Heart Failure Approach 
We demonstrated that a multi-biomarker approach reflecting the multi-systemic character of heart 
failure is better than the gold standard of NT-proBNP. Our multi-variable model confirmed the strong 
prognostic value of TGF-β, CT-1, CysC and NT-proBNP in comparison to NT-proBNP alone in patients 
with hypertension. 
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Transforming Growth Factor-Β 
Heart failure itself is associated with adverse structural remodeling, which is caused by alterations in 
volume or pressure load, local ischemia, fibrosis and myocyte death due to apoptosis or necrosis [19].  
The development of adverse structural remodeling is mainly characterized by an interplay between 
fibroblasts and paracrine signaling proteins such as transforming growth factor β1 (TGF-β1) [19].  
TGF-β1 is one of three isoforms of the TGF-β superfamily. TGF-β1 is a central regulator of cardiac 
fibrosis. Alterations in the structure of cardiac tissue, particularly fibrous tissue transformation, are 
considered to be the major cause of cardiac remodeling. The accumulation of extracellular matrix 
increases myocardial stiffness and consequently impairs contractile behavior of the heart muscle [20]. 
Therefore, serum TGF-β1 may be a marker of chronic tissue transformation rather than a valuable 
functional parameter of left ventricular performance such as NT-proBNP. TGF-β1 is generally bound 
within a large latent complex with a half-life of about 90 min. Biological activity requires release of 
TGF-β1 from the latent complex, which shortens the half-life to only 2 min [21]. 
A higher release from the inactive latent complex and a higher consumption of the active measureable 
serum TGF-β1 molecule in the context of cardiac fibrosis may explain the decrease of measurable serum 
TGF-β1 levels in peripheral blood in patients with heart failure. This supports experimental data from 
the literature, in which natriuretic peptides have been shown to suppress adverse structural remodeling 
in the atria and ventricles. Atrial natriuretic peptide (ANP) and BNP inhibit collagen synthesis previously 
induced before by angiotensin II, endothelin and specific fibroblast growth factors, via influencing its 
mRNA level [22]. In a mouse model, ANP inhibited TGF-β1-induced myofibroblast transformation, 
proliferation and collagen synthesis [23]. Therefore, natriuretic peptides reveal anti-fibrotic effects in  
a paracrine and protective manner and may be local regulators of cardiac remodeling. Behnes et al. [20] 
investigated serum levels of TGF-β1 in 401 patients with atrial fibrillation and congestive heart failure. 
Patients with heart failure had lower TGF-β1 levels than those without it (p = 0.0005). Similarly, in our 
study, patients with hypertension and heart failure had lower TGF-β levels than those with hypertension 
alone. This decrease may result from a higher consumption of TGF-β1 within the impaired myocardium 
or anti-fibrotic functions of natriuretic peptides. However, in our analysis, low TGF-β1 serum levels 
were significantly increased in patients suffering from arterial hypertension and heart failure. 
Cardiotrophin-1 
Cardiotrophin-1 (CT-1) is a newly identified member of the interleukin-6 (IL-6) family of cytokines 
and one of the endogenous ligands for gp130 signaling pathways in the heart. CT-1 induces hypertrophic 
growth and contractile dysfunction in cardiomyocytes. CT-1 is increased in various cardiovascular 
diseases, including hypertension and chronic heart failure. In the study of Celik et al. [24] plasma level of 
CT-1 was associated with diastolic heart failure and estimated left ventricular filling pressures and 
correlated positively with NT-proBNP (p = 0.001, r = 0.349). 
The study of Lopez et al. [25], which investigated the association between CT-1 and left ventricular 
end-diastolic stress and myocardial fibrosis in hypertensive patients with heart failure, revealed  
that plasma CT-1 and NT-proBNP and serum biomarkers of myocardial fibrosis (carboxy-terminal  
pro-peptide of procollagen type I and amino-terminal pro-peptide of procollagen type III) were increased 
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(p < 0.001) in hypertensive patients with heart failure in comparison to controls. In vitro, CT-1 
stimulated the differentiation of human cardiac fibroblast to myofibroblasts (p < 0.05) and the expression 
of procollagen type I (p < 0.05) and III (p < 0.01) mRNAs [25]. 
In the study of Ravassa et al. [26], serum CT-1 was increased in hypertensive patients as compared 
to normotensive patients. The association between CT-1 and myocardial systolic function was independent 
of left ventricular mass even in patients with left ventricular hypertrophy (LVH) or inappropriate left 
ventricular mass (iLVM). Moreover, there was a significant increase in serum CT-1 in hypertensive 
patients with LVH or iLVM, especially in those in whom LVH or iLVM was accompanied by impaired 
myocardial systolic function, as compared to the remaining hypertensive patients and normotensive 
patients [26]. 
The meta-analysis of Song et al. [27] including results from 18 published studies demonstrated 
associations between CT-1 level and hypertension (n = 8), cardiac hypertrophy (n = 9) and heart  
failure (HF) (n = 10). The serum levels of CT-1 were significantly higher in patients with LVH or  
heart failure compared with controls. Subgroup analysis revealed that CT-1 levels were highest in  
patients with hypertension-induced hypertrophy and heart failure and slightly lower in patients with 
hypertension-induced LVH without heart failure [27]. Increased plasma CT-1 levels are associated with 
risk of HF in hypertensive patients. The excess of CT-1 is associated with increased collagen in the 
myocardium of hypertensive patients with heart failure. It is suggested that exaggerated cardiomyocyte 
production of CT-1 in response to increased left ventricular end-diastolic stress may contribute to fibrosis 
through the stimulation of fibroblasts in heart failure of hypertensive origin [25]. CT-1 may serve as  
a novel biomarker in the determination of prognosis in hypertensive patients. 
Cystatin C 
Cystatin C (CysC) is a small, low-molecular weight protein from the group of cysteine proteinase 
inhibitors [28]. It is produced by all nucleated cells in the body and secreted into the extracellular space 
at a steady rate [28]. With low molecular weight and a high isoelectric point, it readily undergoes 
glomerular filtration. In the proximal tubule it is absorbed and then catabolized, and therefore does not 
return to the circulation [28]. It is not excreted in the urine, so the clearance of CysC cannot be 
determined, while its concentration in plasma correlates with the GFR [29]. Plasma CysC has  
a significant advantage over other markers clinically used to estimate GFR [28,29]. It is more accurate 
than plasma creatinine or creatinine clearance (according to Cockcroft-Gault) and more reliable  
than 24 h creatinine clearance [28,29]. 
Impaired renal function is an independent marker for LVH and a good predictor of morbidity and 
mortality in cardiovascular disease [27]. In patients with chronic kidney disease, there is a significant 
association between decreased eGFR and LVH. Renal impairment is an indicator of the degree of heart 
failure and contributes to its progression [30]. 
LVH is an important form of target organ damage in essential hypertension [31]. Furthermore, LVH 
is an independent risk factor for cardiac death, arrhythmia and heart failure. In the study of Li et al. [31], 
there was a positive correlation between serum CysC levels and inter-ventricular septal thickness, 
posterior wall thickness and left ventricular weight index, and the serum level of CysC was an 
independent marker for hypertensive LVH. 
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Elevated CysC levels are an independent risk factor for increased mortality in elderly heart failure 
patients [29]. 
In the study of Manzano-Fernandez et al. [32], the authors compared the prognostic value of CysC 
with creatinine and the MDRD equation to evaluate whether it provides complementary information to 
cardiac biomarkers in the risk stratification of an unselected cohort of patients with acute heart failure [32]. 
In contrast to creatinine and the MDRD equation, the highest CysC tertile (>1.50 mg/L) was  
a significant independent risk factor for adverse events (hazard ratio (HR) 3.08, 95% CI 1.54–6.14,  
p = 0.004) [32]. A multi-marker approach combining cardiac troponin T, NT-proBNP and CysC 
improved risk stratification further, showing that patients with two (HR 2.37, 95% CI (1.10–5.71)) or  
three (HR 3.64, 95% CI (1.55–8.56)) elevated biomarkers had a higher risk for adverse events than 
patients with lack of elevated biomarkers (p for trend = 0.015) [32]. 
Moran et al. [33] examined 4453 subjects aged 65 years or older without heart failure at baseline from 
the Cardiovascular Health Study in order to analyze the association of CysC with the risk of incident 
heart failure with normal ejection fraction (HFNEF) and risk of heart failure with reduced ejection 
fraction (HFREF). During eight years of follow-up, 167 cases of incident HFNEF and 206 cases of 
incident HFREF occurred; increased risk of HFNEF was apparent only in the highest CysC quartile 
(HR 2.25; 95% CI (1.33–3.80)), while a linear trend was present for HFREF [33]. 
Serum CysC is a novel and stable biomarker not influenced by sex, age, exertion, diet, body  
mass index, muscle mass or serum creatinine [31]. The increased predictive power provided by our  
multi-biomarker panel might help to more accurately identify high-risk patients who may benefit from 
a more aggressive treatment. 
2.5. Limitations of the Study 
The study involved a relatively small number of patients, and the findings need to be confirmed in  
a larger population. The present study was conducted as a prospective, consecutive recruitment of 
patients with hypertension. 
3. Experimental Section 
3.1. Study Population 
There were 120 hypertensive patients consecutively included in the study between October 2012 and 
April 2014. The exclusion criteria were as follows: Unstable hypertension, New York Heart Association 
(NYHA) class IV heart failure, evidence of pulmonary hypertension on echocardiography, obstructive 
or restrictive pulmonary disease, hyperthyroidism and hypothyroidism, pregnancy and lactating, 
hemodynamically significant acquired heart defects with the exception of mitral incompetence 
secondary to left ventricular dilatation, cancer, significant anemia, abuse of alcohol or drugs, chronic 
inflammatory and other diseases, operation or severe injury during a month prior to blood collection or 
lack of informed consent to participate in the study. 
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All patients were divided into two groups: 60 patients without heart failure (non-HF group) and  
60 patients with overt systolic heart failure (left ventricular ejection fraction (LVEF) <50% and clinical 
symptoms) (HF group). Dyspnea was graded on the basis of the NYHA functional classification [34]. 
Angina pectoris was graded on the basis of the Canadian Cardiovascular Society (CCS) scale [35]. 
Fasting venous blood samples were drawn in the morning and the obtained serum was frozen at  
the temperature of −70 °C. Estimated glomerular filtration rate (eGFR) was calculated using the 
Modification of Diet in Renal Disease (MDRD) formula [36]. Systolic and diastolic arterial pressures 
were measured using a sphygmomanometer and stethoscope. 
Approval from the Bioethics Commission of the Medical University of Lodz (No. RNN/80/12/KB) 
was obtained. Written informed consent was obtained from all the patients. 
3.2. Biomarker Tests 
The concentrations of NT-proBNP, cardiotrophin-1 (CT-1), cystatin C (CysC), tumor necrosis factor α 
(TNF-α), collagen III N-terminal propeptide (PIIINP), syndecan-4, interleukin-1 receptor-like protein 1 
(IL1RL1), transforming growth factor β 1 (TGF-β1) and lipocalin-2/NGAL were determined using the 
EMax Endpoint ELISA Microplate Reader analyzer (Molecular Devices, Sunnyvale, CA, USA).  
TNF-α was analyzed with the enzyme-linked immunosorbent assay (Diaclone/Gen-Probe, San Diego, 
CA, USA), with two polyclonal antibodies directed against TNF-α. Determination of NT-proBNP and 
CT-1 was performed with reagents of USCN Life Science Inc. (Wuhan, China)/Cloud-Clone Corp 
(Wuhan, China), using a sandwich ELISA assay according to the manufacturer’s protocol. Measurement 
of CysC was performed using a sandwich enzyme immunoassay (BioVendor, Brno, Czech Republic) 
developed for the quantitative measurement of this marker in human serum. Analysis of the concentration 
of PIIINP, syndecan-4 and IL1RL1 was performed with a USCN Life Science Inc./Cloud-Clone Corp 
kit, using a sandwich ELISA assay according to the manufacturer’s protocol. Measurement of TGF-β1 
was performed using a sandwich enzyme immunoassay (Gen-Probe Diaclone SAS, Besançon, France) 
designed for the quantitative detection of TGF-β1 levels in cell culture supernatants, human serum, 
plasma or other body fluids. Determination of lipocalin-2/NGAL was conducted using the BioVendor 
Human Lipocalin-2/NGAL ELISA sandwich enzyme immunoassay. Analysis of the concentration of 
galectin-3 (GAL3) was performed with a USCN Life Science Inc./Cloud-Clone Corp kit, using a 
sandwich ELISA assay. 
3.3. Echocardiography 
All patients were examined following a standardized protocol using an ALOKA Α 10 Premier 
(Tokyo, Japan) with a 3–11 MHz probe. 
Quantitative echocardiography was used following current guidelines [37]. Left ventricular volumes 
and ejection fraction (EF) were determined by biplane Simpson’s method. Left ventricular mass was 
calculated using the Devereux formula. The early (E) and atrial filling (A) peak velocities, E/A ratio, 
deceleration time of early filling and isovolumic relaxation time were measured from transmitral flow [37]. 
  
Int. J. Mol. Sci. 2015, 16 10730 
 
 
3.4. Statistical Analysis 
The STATISTICA 10 software package (StatSoft, Cracov, Poland) was used for analysis. All values 
presented are the mean ± standard deviation (SD) for continuous variables and the number of patients 
and the percentage of total patients for categorical variables. The Shapiro-Wilk test was used to assess 
the normality of distribution. To study the relationship between qualitative variables, the chi-square test 
for independence or chi-square test with Yates’s correction and the chi-square test for maximum 
likelihood were used. To compare two groups, Student’s t test for continuous and discrete variables 
with normal distribution and non-parametric Mann-Whitney U test if the distribution was not  
normal were applied. 
For quantitative variables (continuous and discrete) to evaluate correlations between variables, 
Spearman’s rank correlation coefficient was used. Variables significant in univariate analysis 
(significance level p < 0.10) were used for the construction of a stepwise logistic regression model. The 
quality of the models and the usefulness of the markers were evaluated using receiver operating 
characteristic (ROC) curves, tables of reclassification [38,39], meters NRI (net reclassification 
improvement) and IDI (integrated discrimination improvement) [40,41]. Results were considered 
significant at p < 0.05. 
4. Conclusions 
NT-proBNP, due to a variety of non-cardiac factors that influence its level, is not sufficient to identify 
heart failure in patients with hypertension. Biomarkers with different pathophysiological backgrounds 
(NT-proBNP, TGF-β, CT-1, CysC) enhanced the additive diagnostic value for incident heart failure in 
hypertensive patients compared to NT-proBNP alone. 
Hypertensive patients could be monitored for these indexes once a year or earlier when HF symptoms 
occur to detect potential risk of developing heart failure, renal complications of hypertension and the 
risk of myocardial hypertrophy in order to determine the indications for accurate staging complications 
of hypertension and modification and intensification of pharmacotherapy. 
Additional predictive information from different biological pathways reflects the multi-systemic 
character of heart failure. 
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